Ken, Are you too concerned about your press clippi
Post# of 157737
(Total Views: 337)
Posted On: 10/07/2025 10:18:58 AM
Ken, Are you too concerned about your press clippings and thumbs up or down? I'm not Sam and don't remember Sam. I hope Ken would acknowledge that I give him both Ups and Downs. He offers many reasonable insights.
I'm finishing my 10th year as a CYDY investor. Bought everything through Paulson, so after their cut, all My funds went to the company. Am I better than anyone? Heck no. Your cost basis is lower than mine? I'm happy for you! Plenty of upside for all of us! Some on this board have more shares than were traded on the market yesterday!
I only read this board. I would guess that negative topics are exhaustively discussed on other sites. The opportunity cost of being a 10 year long is negative enough for me and my mental health. I'm not selling. You can add down here; it will pay off!
My construcive suggestions:
1. Thank Stephen Simes for his time on the BOD and replace him. 40 years in biotech leadership and No Successful Drug mentioned in his bio? From my personal observations and experience, including investments with RestorGenex/Diffusion-DFFN (so many shots on goal!), 40 years lets you buy more than one home while keeping the company's burn rate in line with the other high risk non-revenue biotechs. Concern for shareholders? Haha, good one.
2. Thank Tanya Urbach for her time on the BOD and let her devote all of her time to her Family Office duties.
From our shareholder letter --- "To support this next chapter, we welcomed Robert E. Hoffman as our new Chief Financial Officer. An industry veteran with decades of financial and leadership experience, holding various executive and board positions in his biotech career, Robert has already brought significant value to CytoDyn. His expertise in capital markets and strategic planning strengthens our ability to execute, network, and expand our pipeline. We are delighted to have him aboard."
This paragraph seems like the writing of T Urb (Vague superlatives. "delighted"
. No Successful Drug mentioned in his bio.
"... already brought significant value to Cytodyn." ? You mean like share price appreciation? 'Well no, but he was quick to point out that no one in biotech works on Fridays, so that brought significant value to some of our leadership and their significant others.'
I'm guessing again here, but read the other sites to see how the greatness of our molecule could be held down by financing and the passage of time (yes, a race). On my laptop, our Leadership team photos show up like Hollywood Squares. I think the bottom row looks like one job instead of three.
I'm finishing my 10th year as a CYDY investor. Bought everything through Paulson, so after their cut, all My funds went to the company. Am I better than anyone? Heck no. Your cost basis is lower than mine? I'm happy for you! Plenty of upside for all of us! Some on this board have more shares than were traded on the market yesterday!
I only read this board. I would guess that negative topics are exhaustively discussed on other sites. The opportunity cost of being a 10 year long is negative enough for me and my mental health. I'm not selling. You can add down here; it will pay off!
My construcive suggestions:
1. Thank Stephen Simes for his time on the BOD and replace him. 40 years in biotech leadership and No Successful Drug mentioned in his bio? From my personal observations and experience, including investments with RestorGenex/Diffusion-DFFN (so many shots on goal!), 40 years lets you buy more than one home while keeping the company's burn rate in line with the other high risk non-revenue biotechs. Concern for shareholders? Haha, good one.
2. Thank Tanya Urbach for her time on the BOD and let her devote all of her time to her Family Office duties.
From our shareholder letter --- "To support this next chapter, we welcomed Robert E. Hoffman as our new Chief Financial Officer. An industry veteran with decades of financial and leadership experience, holding various executive and board positions in his biotech career, Robert has already brought significant value to CytoDyn. His expertise in capital markets and strategic planning strengthens our ability to execute, network, and expand our pipeline. We are delighted to have him aboard."
This paragraph seems like the writing of T Urb (Vague superlatives. "delighted"
. No Successful Drug mentioned in his bio. "... already brought significant value to Cytodyn." ? You mean like share price appreciation? 'Well no, but he was quick to point out that no one in biotech works on Fridays, so that brought significant value to some of our leadership and their significant others.'
I'm guessing again here, but read the other sites to see how the greatness of our molecule could be held down by financing and the passage of time (yes, a race). On my laptop, our Leadership team photos show up like Hollywood Squares. I think the bottom row looks like one job instead of three.
(14)
(0)